Society Influences AMA Policy on Diabetes Prevention, Public Health Funding and Sequestration; Society Physician Participation Crucial
Earlier this month, the American Medical Association’s (AMA) House of Delegates (HOD) unanimously adopted a resolution introduced by The Endocrine Society calling for the expansion of the National Diabetes Prevention Program (NDPP). The NDPP is a...
|
FDA Incorporates Society Recommendations in Final Guidance for Artificial Pancreas
The U.S Food and Drug Administration (FDA) has released the final artificial pancreas guidance that provides direction for researchers to study the effectiveness of artificial pancreas (AP) device systems in the treatment of type 1 diabetes in an outpatient setting...
|
NIDA and NIAAA to Remain Separate
After deliberating a recommendation from the National Institutes of Health’s (NIH) Scientific Management Review Board (SMRB), NIH Director Francis Collins announced on November 16 that NIH will not restructure to combine the National Institute on Drug Abuse (NIDA)...
|
Society Supports Healthy People 2020 Diabetes Goals through Coalition Efforts
The Diabetes Advocacy Alliance (DAA), of which The Endocrine Society is a founding member, has developed a new strategic partnership with the U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion (ODPHP) designed...
|
Society Webinar on Hypertriglyceridemia Tonight
The webinar on the Society’s latest clinical practice guideline, Evaluating and Treating Hypertriglyceridemia, will be presented tonight, November 28, at 7:00 pm ET. This 60-minute interactive webinar, led by Drs. Lars Berglund and John Brunzell, was originally scheduled...
|
Amgen Releases Drug Warning for Prolia
As part of the communication plan for its risk evaluation and mitigation strategy (REMS), Amgen has released a Dear Healthcare Provider letter regarding the risks associated with the use of Prolia® (denosumab). The letter communicates the risk of atypical femoral...
|
